Palisade Bio Q2 EPS Lifted by Brookline Capital Management

Palisade Bio, Inc. (NASDAQ:PALI) – Investment analysts at Brookline Capital Management raised their Q2 2025 EPS estimates for shares of Palisade Bio in a research report issued to clients and investors on Tuesday, May 13th. Brookline Capital Management analyst K. Raja now forecasts that the company will earn ($0.48) per share for the quarter, up from their prior forecast of ($0.84). Brookline Capital Management currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Palisade Bio’s current full-year earnings is ($12.43) per share. Brookline Capital Management also issued estimates for Palisade Bio’s Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($1.01) EPS, FY2026 earnings at ($0.60) EPS, FY2027 earnings at ($0.59) EPS and FY2029 earnings at ($1.11) EPS.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.37.

Palisade Bio Stock Up 1.0%

Palisade Bio stock opened at $0.69 on Friday. Palisade Bio has a 52 week low of $0.60 and a 52 week high of $6.44. The firm’s 50-day simple moving average is $0.74 and its 200 day simple moving average is $1.39. The firm has a market capitalization of $3.29 million, a PE ratio of -0.05 and a beta of 1.46.

Institutional Investors Weigh In On Palisade Bio

Institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. purchased a new position in Palisade Bio in the 3rd quarter valued at about $29,000. Armistice Capital LLC lifted its holdings in Palisade Bio by 37.4% in the 1st quarter. Armistice Capital LLC now owns 144,764 shares of the company’s stock valued at $99,000 after purchasing an additional 39,397 shares in the last quarter. Finally, Cetera Investment Advisers purchased a new position in Palisade Bio in the 4th quarter valued at about $116,000. 11.79% of the stock is currently owned by hedge funds and other institutional investors.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.